Detalles de la búsqueda
1.
Response to Pralsetinib in Multi-Drug-Resistant Breast Cancer With CCDC6-RET Mutation.
Oncologist
; 2023 May 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37141396
2.
HER2-positive breast cancer progresses rapidly after pyrotinib resistance: acquired RET gene fusion and TP53 gene mutation are potential reasons.
Anticancer Drugs
; 34(10): 1196-1201, 2023 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36689646
3.
Potential mechanism of pyrotinib-induced diarrhea was explored by gut microbiome and ileum metabolomics.
Anticancer Drugs
; 34(6): 747-762, 2023 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36378136
4.
The Real-world Therapeutic Analysis of First-line Immunotherapy in Chinese Patients with Drive Gene Positive for Advanced Non-Small Cell Lung Cancer.
J Cancer
; 14(6): 952-965, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37151388
5.
Clinical characteristics and prognostic factors of patients with non-small cell lung cancer having HER2 alterations.
J Cancer Res Clin Oncol
; 149(5): 2029-2039, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35829744
6.
Opportunities and challenges of immune checkpoint inhibitors for extensive-stage small-cell lung cancer.
Cancer Innov
; 1(2): 183-193, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-38090647
7.
Effects of Shenling Baizhu powder on pyrotinib-induced diarrhea: analysis of gut microbiota, metabonomics, and network pharmacology.
Chin Med
; 17(1): 140, 2022 Dec 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-36528679
Resultados
1 -
7
de 7
1
Próxima >
>>